Sierra Oncology (NASDAQ:SRRA) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16), MarketWatch Earnings reports.
Shares of NASDAQ SRRA traded down $0.05 during midday trading on Friday, hitting $2.05. 869,600 shares of the stock traded hands, compared to its average volume of 520,772. The stock has a market capitalization of $186.52 million, a price-to-earnings ratio of -2.43 and a beta of 2.47. Sierra Oncology has a one year low of $1.41 and a one year high of $4.09.
Several equities analysts recently issued reports on the company. BidaskClub raised Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Saturday, June 16th. ValuEngine raised Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research raised Sierra Oncology from a “sell” rating to a “hold” rating and set a $2.75 price target on the stock in a report on Wednesday, May 16th.
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Featured Story: What are CEFs?
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.